Arterial Occlusive Diseases  >>  Tekturna (aliskiren)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tekturna (aliskiren) / PDL
NCT01067326: The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis

Terminated
3
22
US
Aliskiren, Tekturna, Rasilez, Placebo
Mayo Clinic, National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Novartis
Endothelial Dysfunction
12/11
12/11
AQUARiUS, NCT00853827 / 2008-006447-40: Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

Completed
3
613
US, Canada, Europe, RoW
Placebo, Aliskiren
Novartis Pharmaceuticals, The Cleveland Clinic
Coronary Artery Disease (CAD), Coronary Atherosclerosis
01/13
01/13
NCT01417104: Aliskiren Effect on Aortic Plaque Progression

Terminated
2/3
71
US
Aliskiren, Tekturna, Placebo, Sugar Pill
Ohio State University, Novartis
Atherosclerosis
12/11
01/12

Download Options